1466 — Baijin Life Science Holdings Cashflow Statement
0.000.00%
Last trade - 00:00- HK$525.23m
- HK$593.97m
- HK$135.56m
- 14
- 12
- 48
- 11
Annual cashflow statement for Baijin Life Science Holdings, fiscal year end - March 31st, HKD millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | — |
| Source: | ARS | ARS | ARS | ARS | |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | fx Preliminary |
| Net Income/Starting Line | -52.1 | -15.5 | 8.73 | -8.53 | — |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 39.1 | 11.1 | -30.3 | -14.8 | — |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -5.39 | 4.15 | -1.4 | 15 | — |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -16.2 | 1.11 | -21.5 | -6.46 | — |
| Capital Expenditures | -0.025 | -0.046 | -0.026 | -0.179 | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.163 | -0.014 | 35.3 | 4.92 | — |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 0.138 | -0.06 | 35.3 | 4.74 | — |
| Financing Cash Flow Items | -5.65 | -3.55 | -0.067 | -0.037 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 6.77 | -1.72 | 3.7 | 0.819 | — |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -10.1 | -0.839 | 17.7 | -3.38 | — |